Could a prostate cancer imaging tool help fight brain tumors?

NCT ID NCT07428213

Not yet recruiting Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special PET scan (PSMA PET) can detect a protein on recurrent meningiomas, a common brain tumor. If the protein is present, it might allow a new type of targeted radiation therapy. The study involves 40 adults whose meningioma has come back after standard treatments. The goal is to see if enough tumors show the protein to justify a future treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA PET imaging (a radioactive tracer for scans)
What this could lead to: If successful, this could pave the way for a new targeted radiation therapy for aggressive, recurrent meningiomas that currently have no standard treatment.
What could go wrong: This is a small, early imaging study, not a treatment trial. It only checks if the target is present; a therapy trial would still need to be done. The approach may not work for all tumor grades.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

Hôpital Louis Pradel

Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.